Sparsentan and the Expanding Landscape of IgA Nephropathy Treatment

Clin J Am Soc Nephrol. 2024 Jan 1;19(1):122-125. doi: 10.2215/CJN.0000000000000268. Epub 2023 Jul 27.

Authors

Vimal K Derebail¹, Patrick H Nachman²

Affiliations

¹ UNC Kidney Center , Division of Nephrology and Hypertension , Department of Medicine , University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
² Division of Nephrology and Hypertension , Department of Medicine , University of Minnesota, Minneapolis, Minnesota.

PMID: 37499685
PMCID: PMC10843334 (available on 2025-01-01)
DOI: 10.2215/CJN.0000000000000268

No abstract available

MeSH terms

Glomerulonephritis, IGA* / drug therapy
Glomerulonephritis, IGA* / therapy
Humans
Pyrimidines
Sulfonamides / therapeutic use
Treatment Outcome

Substances

macitentan
Sulfonamides
Pyrimidines